Research evidence / Overview of studies for Canakinumab
Cryopyrin-Associated Periodic Syndromes (CAPS)
Research into canakinumab for CAPS (a group of rare, lifelong inflammatory disorders) has primarily focused on studies that compare its use to a placebo (a dummy treatment). These are often called randomized controlled trials, which are considered a robust way to study a new treatment.
Research has explored whether treatment with canakinumab is associated with reduced symptoms during these flare-ups. Some studies suggested that a higher proportion of individuals who received the treatment met the pre-defined study endpoint (clinical response) compared to those who received a placebo. Follow-up studies, where participants continued to receive the treatment, investigated whether individuals maintained the initial study response.
However, research in this area also faces some limitations. Since CAPS is a very rare disease, the studies are often relatively small, and this can limit the certainty of the findings. While the initial findings suggest a potential association with improved outcomes, more long-term evidence is important to understand the treatment's effects over many years. Also, understanding how the treatment affects different subtypes of CAPS and people of varying ages is an area where ongoing research is valuable.
Active Systemic Juvenile Idiopathic Arthritis (SJIA)
For SJIA, a type of childhood arthritis that involves inflammation throughout the body, research has included studies designed to look at changes in disease symptoms. The studies conducted included children and adolescents who had not responded adequately to other standard treatments, or who were still experiencing active disease flares.
Research has explored whether the treatment is associated with a reduction in the signs and symptoms of active SJIA, such as fever and joint pain, and whether it affects lab tests that measure inflammation. Some studies have compared canakinumab to a placebo, while others have looked at the effects when added to standard treatment. The general pattern observed is that studies have investigated whether a proportion of children and adolescents met the metrics for changes in disease activity when receiving canakinumab.
Areas where research is still developing include understanding the long-term impact on growth and overall quality of life in children and adolescents. While the initial studies report findings regarding immediate symptoms, more information is needed to clarify the long-term effects on the developing bodies of this special population. It is also not completely clear what happens when treatment is stopped, and this remains a focus of ongoing study.
Adult-Onset Still’s Disease (AOSD)
Research into canakinumab for AOSD, which is essentially the adult form of SJIA, has followed a similar path to the studies in children. The goal has been to see if the treatment is associated with management of the severe inflammatory symptoms that characterize this condition in adults, such as fever, rash, and arthritis.
Studies conducted for AOSD suggest that researchers examined whether the treatment is associated with adult patients achieving and maintaining a state of reduced disease activity. For people experiencing active flares, research indicates that the studies investigated whether the treatment affects the inflammatory process and symptom levels. The studies conducted were often randomized controlled trials comparing the treatment to a placebo, providing a reasonable basis for the initial findings.
A key challenge in the research is that AOSD is also an uncommon disease, which means the number of people included in the studies is often limited. While short- to medium-term results are available, research is needed to better understand the long-term outcomes and the potential for a sustained response over many years in a broader group of adult patients. Also, the research base is smaller compared to some other chronic conditions, and more experience with different patient groups is valuable.
Tumour Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS)
Studies exploring canakinumab for TRAPS—another type of rare, inherited inflammatory disorder—have focused on people who experience recurrent, severe fevers and other inflammatory symptoms. Given the rarity of TRAPS, the research studies have been small and specifically tailored to this patient group.
Research so far indicates that studies have explored whether the treatment is associated with a reduction in the frequency and severity of inflammatory flares for people with TRAPS. Studies suggested that the frequency of recurrent flares was lower among individuals receiving canakinumab, and a higher proportion met the definition of a reduced symptom state compared to those receiving a placebo. This suggests that the underlying inflammatory process was a focus of investigation.
As with other rare diseases, the research evidence is limited by the small size of the studies. While the findings suggest an association, ongoing research is necessary to fully understand the treatment's effect across the wide range of genetic variations seen in people with TRAPS, and to gather more data on the very long-term effects of the treatment.
Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
The use of canakinumab has also been investigated for HIDS/MKD, another rare inherited syndrome characterized by recurring fevers and inflammation. The research has been conducted in a similar structure to the other rare periodic fever syndromes, involving small studies.
Research has explored whether the treatment is associated with a reduction in the number of painful and debilitating fever attacks that people with HIDS/MKD experience. The findings indicate that researchers examined whether a number of individuals on the treatment showed a clinical response, meaning a reduction in the severity of their symptoms and the frequency of their fevers, compared to those receiving a placebo.
The evidence for HIDS/MKD is limited by the small number of people who have participated in studies due to the rarity of the condition. While the initial findings are available for the acute symptoms, more research is needed to fully clarify the long-term impact on the progression of the disease and to understand the optimal ways to manage the treatment over many years.
